<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198943">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500708</url>
  </required_header>
  <id_info>
    <org_study_id>CDx_000003</org_study_id>
    <nct_id>NCT00500708</nct_id>
  </id_info>
  <brief_title>Diagnostic Investigation of Sudden Cardiac Event Risk</brief_title>
  <acronym>DISCERN</acronym>
  <official_title>Identifying Markers That Predict Ventricular Arrhythmia Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioDx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) affects 5 million Americans, with 500,000 new cases diagnosed and 250,000
      deaths each year. The two major causes of morbidity and mortality in HF are pump failure and
      sudden, lethal ventricular arrhythmias, the latter of which accounts for 40-50% of HF
      deaths. Arrhythmias may be precipitated by a complex interaction of genetic and
      environmental factors. Establishing increased risk for arrhythmias before a severe
      life-threatening event is critically important. However, this remains a significant medical
      challenge.

      Several genetic mutations associated with rare, inherited arrhythmia disorders have been
      identified. The aim of this study is to identify novel genetic and other biological markers
      that distinguish patients at increased risk for lethal ventricular arrhythmias in a broader
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 1, 2011</completion_date>
  <primary_completion_date type="Actual">August 1, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene discovery</measure>
    <time_frame>up to 3 years</time_frame>
    <description>whole genome association study (WGAS)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1564</enrollment>
  <condition>Arrhythmia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, buffy coat, spun plasma, saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient's with ventricular dysfunction (low ejection fraction) undergoing implantation of
        ICD or CRT-D for primary prevention. Patient's may be enrolled at time of implant or
        during follow-up in electrophysiology clinic as long as full device records are available
        since time of implant.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Implantable cardiac defibrilIator (ICD) or cardiac resynchronization therapy
             defibrillator (CRT-D) implanted for primary prevention

          -  Left ventricular ejection fraction (LVEF) â‰¤ 50 %

          -  Ability to collect clinical follow-up and endpoint information, including device
             interrogation data

        Exclusion Criteria:

          -  Congenital heart disease

          -  Known inherited arrhythmia disorder

          -  Organ transplantation

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS</last_name>
    <role>Study Director</role>
    <affiliation>CardioDx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alaska Heart Institute</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute and Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Allegheny Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hranitzky PM, Sehnert AJ, Blanchard JL, et al. Abstract 16410: Identification of novel genetic markers associated with lethal ventricular arrhythmias in heart failure patients: genome wide association study in the DISCERN cohort. Circulation. 2010;122. Abstract 16410.</citation>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>July 11, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Implanted Cardioverter Defibrillator</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Molecular Genetics</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
